Table 1 Patient characteristics
Number of patients | n = 125 |
|---|---|
Median (range) age at diagnosis in years | 55 (28–85) |
Performance status WHO: | |
▪ 0 | 15.2 % (19/125) |
▪ 1 | 77.6 % (97/125) |
▪ 2 | 7.2 % (9/125) |
BSA (m2) | 1.69 (95 % CI; 1.65–1.72) |
FIGO stage: | |
▪ I | 11.2 % (14/125) |
▪ II | 8.0 % (10/125) |
▪ IIIA | 5.6 % (7/125) |
▪ IIIB | 7.2 % (9/125) |
▪ IIIC | 56.0 % (70/125) |
▪ IV | 12.0 % (15/125) |
Chemotherapy regimen: | |
▪ Paclitaxel/cisplatin | 43.2 % (54/125) |
▪ Paclitaxel/carboplatin/ caelyx | 8.8 % (11/125) |
▪ Paclitaxel/carboplatin | 36.8 % (46/125) |
▪ Carboplatin | 8.8 % (11/125) |
▪ Paclitaxel/carboplatin/epirubicin | 1.6 % (2/125) |
▪ Gemcitabine/ cisplatin | 0.8 % (1/125) |
Type of histology: | |
▪ Serous | 54.4 % (68/125) |
▪ Endometrioid | 26.4 %(33/125) |
▪ Mucinous | 7.2 % (9/125) |
▪ Clear cell | 4.0 % (5/125) |
▪ Mixed | 2.4 % (3/125) |
▪ Unspecified | 5.6 % (7/125) |
Grading: | |
▪ 1 | 3.2 % (4/125) |
▪ 2 | 32.8 % (41/125) |
▪ 3 | 23.2 % (29/125) |
▪ Unspecified | 40.8 % (51/125) |
Primary surgery: | |
▪ Radical | 19.2 % (24/125) |
▪ Optimal (<1 cm) | 42.4 % (53/125) |
▪ Suboptimal (>1 cm) | 38.4 % (48/125) |